Repligen Corporation $RGEN Shares Sold by TD Asset Management Inc

TD Asset Management Inc cut its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 66.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 26,628 shares of the biotechnology company’s stock after selling 52,596 shares during the period. TD Asset Management Inc’s holdings in Repligen were worth $3,559,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in RGEN. Wealth Enhancement Advisory Services LLC raised its holdings in Repligen by 1.9% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 4,001 shares of the biotechnology company’s stock worth $584,000 after purchasing an additional 75 shares in the last quarter. Hilltop National Bank raised its stake in shares of Repligen by 8.0% in the 3rd quarter. Hilltop National Bank now owns 1,276 shares of the biotechnology company’s stock worth $171,000 after buying an additional 95 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Repligen by 4.3% in the 2nd quarter. ProShare Advisors LLC now owns 2,316 shares of the biotechnology company’s stock worth $288,000 after buying an additional 96 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Repligen by 17.0% in the third quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 97 shares during the period. Finally, State of Michigan Retirement System boosted its stake in Repligen by 0.8% during the second quarter. State of Michigan Retirement System now owns 12,553 shares of the biotechnology company’s stock valued at $1,561,000 after buying an additional 100 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Insider Buying and Selling at Repligen

In related news, Director Karen A. Dawes sold 275 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the completion of the sale, the director owned 91,821 shares in the company, valued at $14,783,181. This represents a 0.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.20% of the company’s stock.

Repligen Trading Down 1.5%

Shares of RGEN stock opened at $123.06 on Wednesday. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $175.77. The company has a market cap of $6.93 billion, a PE ratio of 144.78, a price-to-earnings-growth ratio of 2.43 and a beta of 1.14. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26. The business’s 50 day moving average is $152.50 and its two-hundred day moving average is $147.09.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business had revenue of $197.91 million for the quarter, compared to analyst estimates of $192.23 million. During the same period last year, the business posted $0.44 EPS. Repligen’s revenue was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities analysts predict that Repligen Corporation will post 1.72 EPS for the current year.

Analysts Set New Price Targets

RGEN has been the topic of several research reports. UBS Group dropped their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Wall Street Zen cut shares of Repligen from a “buy” rating to a “hold” rating in a report on Saturday. Barclays dropped their price objective on shares of Repligen from $200.00 to $175.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Weiss Ratings raised Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, February 17th. Finally, Wells Fargo & Company reduced their price target on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.58.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.